NewsRoom Articles - Page 27 of 214

FridayOct 25, 2024 10:00 am

Tech Giants Unveil AI Tools to Support e-Commerce, Healthcare and Video Production

In the last fortnight, leading technology companies have unveiled a number of artificial intelligence tools which could have a huge impact on the e-commerce, healthcare and video production fields. Adobe released its Firefly Video production tool. The model allows corporate users to reduce the costs associated with video production and also streamline the entire process. With the AI tools from Adobe, users can provide text prompts in any of at least 100 supported languages and have custom videos generated. Experts clarify that the efficiency-boosting attributes of these video creation tools shouldn’t be seen as a replacement for humans. Instead, the…

ThursdayOct 24, 2024 10:00 am

Change Healthcare Cyberattack Toll Could Reach Almost $3 Billion This Year

Andrew Witty, the CEO of UnitedHealth Group, gave his testimony on the ransomware attack on Change Healthcare to the Senate Finance Committee in June. The attack occurred in February of this year, with the initial point of entry for the ransomware being a server whose multifactor authentication hadn’t been enabled. This is despite the fact that multifactor authentication is a standard practice for servers exposed to the public internet. After gaining access to the server, the ransomware then acquired access to the Microsoft Active Directory Server. This ransomware attack was a wake-up call to others in the healthcare industry, prompting…

WednesdayOct 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies, Paving the Way for NDA Filings

Annovis Bio received FDA clearance to move forward with Phase 3 trials for buntanetap following an End-of-Phase 2 meeting on October 10, 2024. The pivotal trials will investigate buntanetap’s short-term symptomatic effects and potential long-term disease-modifying benefits in early-stage Alzheimer’s disease (“AD”) patients. Annovis Bio is targeting potential NDA submission within one year of the study’s initiation for symptomatic treatment, based on the results of a well-executed 6-month trial. The FDA raised no safety concerns regarding buntanetap and supported the use of its new crystal form in development. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on…

MondayOct 21, 2024 10:00 am

Study Explores Repurposing Drugs as a Way to Fight Brain Tumor Origins

Glioblastoma multiforme is a common and very aggressive type of cancer that primarily affects an individual’s brain and/or spinal cord. This cancer has an average survival rate of less than 22 months following diagnosis despite standard treatment including chemotherapy, irradiation and surgery. Various factors contribute to this poor outcome, including high tumor recurrence rates, tumor resistance to treatment, and intra-tumoral heterogeneity. In recent years, it has become clear to scientists that not all cells in brain tumors help drive tumor growth. This has led scientists to pay more attention to brain tumor stem cells, which they theorize are the main…

FridayOct 18, 2024 12:00 pm

Clene Inc. (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates, Latest Achievements at Top Investor Conferences

Clene gave a fireside presentation and held one-on-one investor meetings at the 2024 Maxim Healthcare Virtual Summit on October 15. On October 30, Clene will give a presentation and participate in one-on-one meetings at The ThinkEquity Conference 2024 at the Mandarin Oriental Hotel in New York. Clene’s lead drug candidate, CNM-Au8® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions. Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS and is scheduled to have a meeting with the FDA leadership in November. Clene (NASDAQ: CLNN) and its…

FridayOct 18, 2024 10:00 am

Toxic Protein Could Be Behind the Development of Amyotrophic Lateral Sclerosis

New research has found that a toxic protein may affect the skeletal muscle tissues, spinal cord, and brain, aiding the development and progression of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis or ALS in short, is an illness that affects an individual’s nervous system, causing nerve cells in the spinal cord and brain to degenerate. As it progresses, this motor neuron illness leads to muscle weakness and atrophy. The research was carried out by a team of scientists from Penn State College of Medicine. It was based on prior studies which implicated mutations of the superoxide dismutase 1 (SOD1) protein in…

WednesdayOct 16, 2024 10:00 am

Analysis of Medical Records Repeatedly Links Viruses to Alzheimer’s

New research has observed that serious viral infections, including pneumonia and encephalitis, heighten the risk of neurodegenerative illnesses such as Alzheimer’s and Parkinson’s. This comes after previous research found a connection between the Epstein-Barr virus and a heightened risk of developing multiple sclerosis. Michael Nalls, a neurogeneticist and the senior author of the study, revealed that the research team decided to use a data science-based approach for its research. Using this approach, the investigators focused on analyzing medical records, which made it easier to systematically look for all potential links at a go. They focused on the medical records of…

MondayOct 14, 2024 10:00 am

Researchers Shine Spotlight on New Barriers to Vaccination

The 20th century saw many advancements being adopted in the medical field, among them, potable water, penicillin and, most importantly, vaccines. Vaccines have saved millions of lives, from the eradication of smallpox globally in the 1980s to their use in curbing the spread of the coronavirus in 2020. Over the last 10 years, however, rates of vaccination have begun to drop, threatening the great beneficial effects of vaccinations not only in the United States but also around the globe. A recent review examined the new public health and clinical barriers to vaccination in the United States. The review was conducted…

FridayOct 11, 2024 10:00 am

Siblings of Autistic Kids Have Sevenfold Higher Risk of Autism

Autism spectrum disorder is a developmental and neurological disorder that affects how an individual communicates and interacts with others as well as the individual behaves and learns. Now, a new study has determined that siblings of children with autism have a higher likelihood of being diagnosed with the developmental disorder. The research was carried out by researchers from the Baby Siblings Research Consortium and the UC Davis MIND Institute. The researchers’ objective was to determine the likelihood that a child born after an autistic child in one family would have the disorder. Huge increases in autism diagnoses, as observed in…

ThursdayOct 10, 2024 11:15 am

Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements

Proceeds from the offerings will support the company’s operations into the first quarter of 2025. Clene also amended its existing debt facility with Avenue Venture Opportunities Fund, L.P. to reduce or defer future monthly principal payments and to extend principal amortization period and the final maturity date into the first half of 2025. The company’s lead drug candidate, CNM-Au8® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions. Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS, with a meeting scheduled with the FDA before the end…